Pipeline
Advancing drug candidates with the goal of delivering transformative medicines for patients
Our lead clinical-stage programs include VENT-03, a first-in-class inhibitor of cGAS – a preeminent target in I&I that plays a central role in a wide array of conditions – and VENT-02, a potential best-in-class, brain-penetrant inhibitor of NLRP3 – a principal driver of inflammation. We also have multiple programs in discovery and are pursuing a broad pipeline of additional targets.
| Program | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|
| VENT-03 (Oral cGAS inhibitor) | |||||
| Lupus | |||||
| Additional I&I indications | |||||
| VENT-02 (Oral brain-penetrant NLRP3 inhibitor) | |||||
| Parkinson’s disease | |||||
| VENT-01 (Oral systemic NLRP3 inhibitor) | |||||
| Broad range of systemic diseases |  | ||||
| VENT-04 (Oral systemic caspase-4/5 inhibitor) | |||||
| IBD, HS, asthma, COPD | |||||
| Discovery - Powered by ReSOLVE® | |||||
| Wholly-owned programs | |||||
| Partnered programs |  | ||||
| VENT-03 (Oral cGAS inhibitor) | ||
| Lupus | ||
| Phase 2 | ||
| Additional I&I indications | ||
| Phase 1 | ||
| VENT-02 (Oral brain-penetrant NLRP3 inhibitor) | ||
| Parkinson’s disease | ||
| Phase 2 | ||
| VENT-01 (Oral systemic NLRP3 inhibitor) | ||
| Broad range of systemic diseases | ||
| Phase 1 | ||
| VENT-04 (Oral systemic caspase-4/5 inhibitor) | ||
| IBD, HS, asthma, COPD | ||
| IND-Enabling | ||
| Discovery - Powered by ReSOLVE® | ||
| Wholly-owned programs | ||
| Discovery | ||
| Partnered programs | ||
| Discovery | ||
